7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Alois Alzheimer (1864-1915): The Father of Modern Dementia Research and the Discovery of Alzheimer’s Disease

      review-article
      1 , 2 , 3 , 1 , 1 ,
      ,
      Cureus
      Cureus
      biographies, historical vignette, historical vignettes, medical innovation, medical stories

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alois Alzheimer was a German psychologist and neuropathologist who significantly advanced the study of dementia with his discovery of Alzheimer’s disease (AD). Based on his assessment of a 51-year-old female patient with symptoms of presenile dementia and after conducting a postmortem autopsy of her brain, Alzheimer distinguished two neurological substances - senile plaques and neurofibrillary tangles - as unique markers of what was later deemed as AD. He recognized that dementia is not a natural consequence of age but rather a recognizable neurocognitive disorder. Despite the long-lasting criticism of his findings, Alzheimer’s discovery fundamentally altered the landscape of neuropathological studies by establishing that AD was a clinically identifiable disease with distinct markers that could be targeted for treatment. Today, modern research on AD continues to build on the foundation laid by Alzheimer’s discovery.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Current and future treatments for Alzheimer's disease.

          Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as 'disease-modifying' drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. In this review we discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I-III trials.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The discovery of Alzheimer's disease

            On Novembers, 1306, a clinical psychiatrist and neuroanatomist, Alois Alzheimer, reported “A peculiar severe disease process of the cerebral cortex” to the 37th Meeting of South-West German Psychiatrists in Tubingen, He described a 50-year-old woman whom he had followed from her admission for paranoia, progressive sleep and memory disturbance, aggression, and confusion, until her death 5 years later. His report noted distinctive plaques and neurofibrillary tangles in the brain histology. It excited little interest despite an enthusiastic response from Kraepelin, who promptly included “Alzheimer's disease” in the 3ih edition of his text Psychiatrie in 1910. Alzheimer published three further cases in 1909 and a “plaque-only” variant in 1911, which reexamination of the original specimens in 1993 showed to be a different stage of the same process, Alzheimer died in 1915, aged 51, soon after gaining the chair of psychiatry in Breslau, and long before his name became a household word.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Neuropathologic changes in Alzheimer’s disease

                Bookmark

                Author and article information

                Journal
                Cureus
                Cureus
                2168-8184
                Cureus
                Cureus (Palo Alto (CA) )
                2168-8184
                17 October 2024
                October 2024
                : 16
                : 10
                : e71731
                Affiliations
                [1 ] Health Informatics, Rutgers University, Piscataway, USA
                [2 ] Orthopedic Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, USA
                [3 ] Orthopedic Surgery, Orange Orthopedic Associates, West Orange, USA
                Author notes
                Article
                10.7759/cureus.71731
                11568893
                39553038
                d12b5125-5434-4af6-9331-86fdb17de1d6
                Copyright © 2024, Thakor et al.

                This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 17 October 2024
                Categories
                Neurology
                Psychiatry
                Pathology

                biographies,historical vignette,historical vignettes,medical innovation,medical stories

                Comments

                Comment on this article